Scholars Central

Conference abstractPublished 2018

Lessons learned from the failure of Alzheimer’s drug development over the past 20 years

Authors: Brian H Tran, Lloyd L Tran

NeuroActiva Inc., USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There are more than 5.5 million people in the US and 43 million people worldwide that have Alzheimer’s disease in 2017. Growth in the prevalence of Alzheimer’s Disease (AD) over the next few decades is anticipated to result in great pressure on the social and health-care systems of developed and developing economies alike. The current treatment options are considered to be symptomatic. There is an unmet need for therapies that halt or substantially slow disease progression. There were no new drug approvals for treatment of AD; none have been approved in the USA since 2003. Over the past 20 years a majority of failed AD drugs were based on the guiding principle of the amyloid hypothesis, which postulates that accumulation of amyloid plaques trigger a cascade that harms neurons and synapses. Most immunotherapy drugs based on β-secretase, γ-secretase and stimulators of α-secretase have been used to target Aβ pathology include decreasing of Aβ production, preventing aggregation of or stimulating clearance of Aβ. A new non-amyloid approach in the development of a new drug in Phase 2 known as NA-831, a novel neuroprotective and neurogenesis agent for treatment of Alzheimer's disease. The past AD drug development failure and a new clinical strategy for the development of NA-831 is described

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Mental Health & Psychiatry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Mental Health & Psychiatry
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Brian H Tran”
  • BylineArticles whose byline prints “Lloyd L Tran”